22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
When parties begin merger talks, it is with an eye toward getting the deal done, getting the sellers...
Read More >
Join us for the 12th annual “Selecting Project Delivery Methods & Bidding Public Construction Contr...
Read More >
This fall there will be significant labour reforms in the federal sector. As well, consultations wi...
Read More >
Among the numerous worker-protection bills California governor Gavin Newsom signed last month was As...
Read More >
The Federal Trade Commission (“FTC”) has failed – at least for now – in its efforts to derail a ...
Read More >
The Boston Planning and Development Agency (“BPDA”) has approved an amendment to the Boston Zoning...
Read More >